LOVAZA Drug Patent Profile
✉ Email this page to a colleague
When do Lovaza patents expire, and when can generic versions of Lovaza launch?
Lovaza is a drug marketed by Woodward and is included in one NDA.
The generic ingredient in LOVAZA is omega-3-acid ethyl esters. There are thirteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the omega-3-acid ethyl esters profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lovaza
A generic version of LOVAZA was approved as omega-3-acid ethyl esters by GLW on April 7th, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LOVAZA?
- What are the global sales for LOVAZA?
- What is Average Wholesale Price for LOVAZA?
Summary for LOVAZA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 6 |
| Clinical Trials: | 82 |
| Patent Applications: | 222 |
| Drug Prices: | Drug price information for LOVAZA |
| Drug Sales Revenues: | Drug sales revenues for LOVAZA |
| What excipients (inactive ingredients) are in LOVAZA? | LOVAZA excipients list |
| DailyMed Link: | LOVAZA at DailyMed |
Recent Clinical Trials for LOVAZA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Prisma Health-Midlands | Phase 2/Phase 3 |
| James and Esther King Biomedical Research Program | Phase 2 |
| H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
Paragraph IV (Patent) Challenges for LOVAZA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| LOVAZA | Capsules | omega-3-acid ethyl esters | 1 g | 021654 | 3 | 2008-11-10 |
US Patents and Regulatory Information for LOVAZA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Woodward | LOVAZA | omega-3-acid ethyl esters | CAPSULE;ORAL | 021654-001 | Nov 10, 2004 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LOVAZA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Woodward | LOVAZA | omega-3-acid ethyl esters | CAPSULE;ORAL | 021654-001 | Nov 10, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Woodward | LOVAZA | omega-3-acid ethyl esters | CAPSULE;ORAL | 021654-001 | Nov 10, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Woodward | LOVAZA | omega-3-acid ethyl esters | CAPSULE;ORAL | 021654-001 | Nov 10, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LOVAZA
See the table below for patents covering LOVAZA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| New Zealand | 230022 | FATTY ACID COMPOSITIONS CONTAINING OMEGA-3-FATTY ACIDS | ⤷ Sign Up |
| Argentina | 079872 | UN PROCESO PARA DISMINUIR LA CANTIDAD DE CONTAMINANTES MEDIOAMBIENTALES PRESENTES EN UNA MEZCLA | ⤷ Sign Up |
| Ireland | 64524 | Fatty acid composition | ⤷ Sign Up |
| Denmark | 1534807 | ⤷ Sign Up | |
| South Africa | 8905512 | ⤷ Sign Up | |
| Spain | 2018384 | METODO PARA PREPARAR UNA COMPOSICION DE ACIDOS GRASOS. (Fatty acid composition) | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2004007655 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
